This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
United Therapeutics (UTHR) Q1 Earnings Rise, Sales Drop Q/Q
by Zacks Equity Research
United Therapeutics' (UTHR) earnings per share rise in the first quarter. Sales drop sequentially due to unfavorable timing of distributor orders. Shares sink almost 7%.
Top Ranked Growth Stocks to Buy for May 2nd
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, May 2nd:
Top Ranked Growth Stocks to Buy for April 30th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 30th:
Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales
by Zacks Equity Research
The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.
Lilly (LLY) Tops on Q1 Earnings, Raises '18 View, Stock Up
by Zacks Equity Research
Eli Lilly (LLY) beats estimates for both earnings and sales in Q1 and raises guidance for 2018. Shares rise in pre-market trading.
Eli Lilly (LLY) Tops Q1 Earnings & Sales, Ups 2018 View
by Kinjel Shah
Eli Lilly (LLY) beat estimates for both earnings and sales in Q1 and raised the guidance for 2018. Shares declined in pre-market trading.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN
by Zacks Equity Research
Three pharma/biotech bigwigs are set to release earnings report on Apr 24. Let's sneak a peek into how the companies are placed ahead of the upcoming results.
Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Lilly's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Top Ranked Growth Stocks to Buy for April 20th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 20th:
Amgen's Aimovig Reduces Episodic Migraine in 30% Patients
by Zacks Equity Research
Amgen (AMGN) releases full data from the phase IIIb trial, evaluating the efficacy and safety of Aimovig on patients suffering episodic migraine with multiple treatment failures.
5 Drug Stocks Poised to Surpass on Earnings This Quarter
by Zacks Equity Research
The outlook for the upcoming first-quarter results looks bright.
Merck's Keytruda Betters Survival in Lung Cancer Combo Study
by Zacks Equity Research
Merck (MRK) releases complete data from a phase III study showing Keytruda in combination with Lilly's Alimta and platinum chemotherapy reducing death risk by half compared with only chemotherapy.
Celldex's Phase II Breast Cancer Study Fails, Shares Plunge
by Zacks Equity Research
Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastatic breast cancer.
Merck's Keytruda Reduces Death Risk in Melanoma Patients
by Zacks Equity Research
Merck's (MRK) Keytruda significantly prolongs RFS and reduces the risk of disease recurrence or death by 43% versus placebo in a phase III study in high-risk stage III melanoma patients.
AbbVie's RA Candidate Meets Primary Endpoints in Phase III
by Zacks Equity Research
AbbVie's (ABBV) rheumatoid arthritis candidate, upadacitinib, meets both primary and secondary endpoints in the fourth phase III SELECT study for the given indication.
vTv Therapeutics Crashes on Alzheimer's Drug Study Failure
by Zacks Equity Research
vTv Therapeutics (VTVT) shares suffered a major blow when the company's late stage study on lead candidate, azeliragon, for the treatment of Alzheimer's failed.
Merck's Keytruda Offers Survival Benefit in Lung Cancer Study
by Zacks Equity Research
Merck's (MRK) phase III study showed that Keytruda monotherapy led to significantly improved overall survival (OS) as a first-line therapy in certain lung cancer patients.
Novartis and Other Drug Stocks With FDA Catalysts in April
by Kinjel Shah
With just a quarter gone by this year, the FDA has already granted approval to six new treatments.
Top Ranked Growth Stocks to Buy for April 10th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 10th:
Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study
by Zacks Equity Research
A late-stage study evaluating Eli Lilly's (LLY) Cyramza for the second-line treatment of liver cancer patients shows that such patients derived a survival benefit with Cyramza after first-line treatment with Nexavar.
FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus
by Zacks Equity Research
The FDA's refusal to review Alkermes' depression candidate AKLS 5461 has brought depression disease market in focus. Here we take a look at a few companies developing products for this market.
Fast Pipeline Progress Pushes ImmunoGen Above 150% in a Year
by Zacks Equity Research
ImmunoGen's (IMGN) shares shoot up more than 150% in a year's time on rapid pipeline progress, positive study data and strategic collaborations.
FDA Nods for Bristol-Myers' Colorectal Cancer Combo Therapy
by Zacks Equity Research
Bristol-Myers' (BMY) filing for Opdivo in combination with Yervoy gains acceptance from the FDA for treating metastatic colorectal cancer. A response is expected in July, 2018.
The Zacks Analyst Blog Highlights: Nike, Eli Lilly, NVIDIA, L Brands and Alleghany
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Nike, Eli Lilly, NVIDIA, L Brands and Alleghany